Grifols S.A. ADR (GRFS)
NASDAQ: GRFSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
GRFS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $5.55B
- P/E (TTM)
- 9.82
- Forward P/E
- 6.55
- EPS (TTM)
- $0.83
- Dividend yield
- 1.30% ($0.00)
- Ex-dividend date
- Dec 3, 2026
- 52-week range
- 6.96 – 9.77
- Day range
- 8.08 – 8.22
- Volume / Avg
- 848.27K / 628.64K
- Beta
- —
- Shares outstanding
- 258.22M
52-week range
GRFS stock today
Grifols S.A. (GRFS) closed at $8.15 on Nov 20, down 0.61% (-$0.05), versus the S&P 500's 3.70% decline. At this level, GRFS sits in the middle of its 52-week range of $6.96 to $9.77: 16.6% below the high, set on Feb 18, 2026 and 17.1% above the low. GRFS is down 12.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 3.0%.
Grifols S.A. trades at 9.8x its trailing twelve-month earnings per share of $0.83. Its forward P/E of 6.6x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. To receive the next $0.1686 dividend, investors must own shares before the Dec 3 ex-dividend date.
Summary generated from market data by MetaCap's automated system. Methodology
About Grifols S.A.
Company profileGrifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Jose Ignacio Abia Buenache
- Headquarters
- Barcelona, NY
- Employees
- 25,000
- Website
- grifols.com
Analyst forecast
ForecastConsensus (2 analysts)
buy
Avg. price target
$10.37+27.24%
- Strong buy 0
- Buy 1
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Dividends
Dividend history- Annual dividend
- $0.00
- Dividend yield
- 1.30%
- Last payment
- $0.1686
- Ex-dividend date
- Dec 3, 2026
- Pay date
- Dec 11, 2026
GRFS news
All GRFS news- ADMA Surges 20.9% Post Q3 Earnings: Buy, Sell or Hold the Stock?NasdaqADMA, GRFS, TAK
- Grifols Q3 Net Profit Rises, Revenue Up 8.4%; On Track To Meet 2026 GuidanceNasdaq
- Grifols (GRFS) Q3 2026 Earnings Call TranscriptNasdaq
- After Hours Most Active for Sep 23, 2026 : WBD, GRAB, NVDA, NIO, CMCSA, TTD, BMY, GRFS, PBR, RKT, RBLX, ONasdaqGRAB, NVDA, NIO, CMCSA
Grifols S.A. peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LGNDLigand Pharmaceuticals Incorporated | 286.85 | -0.03% | $5.74B | vs GRFS |
| ARWRArrowhead Pharmaceuticals Inc. | 41.37 | -5.22% | $5.85B | vs GRFS |
| SUPNSupernus Inc. | 28.61 | +0.92% | $5.94B | vs GRFS |
| BLTEBelite Bio Inc ADR | 127.38 | -15.65% | $5.17B | vs GRFS |
| MANEVeradermics Incorporated | 119.52 | -3.92% | $5.04B | vs GRFS |
| MIRMMirum Pharmaceuticals Inc. | 96.13 | +0.65% | $6.28B | vs GRFS |
| LQDALiquidia Corporation | 54.43 | -3.88% | $4.90B | vs GRFS |
| ABVXAbivax SA ADR | 73.20 | -9.24% | $6.41B | vs GRFS |
Indexes, lists and sector
Grifols S.A. stock FAQ
What is Grifols S.A.'s stock price today?
GRFS last traded at $8.15 as of Nov 20, 4:00 PM EST, down 0.61% on the day. Prices are delayed at least 15 minutes.
Does Grifols S.A. pay a dividend?
Yes. Grifols S.A. pays $0.00 per share annually, a 1.30% yield. The most recent dividend of $0.1686 had an ex-dividend date of Dec 3, 2026.
What is GRFS's P/E ratio?
GRFS trades at a trailing P/E ratio of 9.82 and a forward P/E of 6.55.
Who is Grifols S.A.'s CEO?
Mr. Jose Ignacio Abia Buenache is the chief executive officer of Grifols S.A. ADR, which has about 25,000 employees.
Has GRFS ever split its stock?
Yes. The most recent GRFS stock split was a 2-for-1 split on Jan 4, 2016, one of 3 splits on record.
What is the GRFS 52-week high?
The 52-week high for GRFS is $9.77 and the 52-week low is $6.96. The stock is currently 16.6% below its high.